Translational Hearing Center
转化听力中心
基本信息
- 批准号:10579956
- 负责人:
- 金额:$ 211.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-05 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAcademic achievementAccelerationAchievementAddressAdmission activityAdvisory CommitteesAffectAgingAttenuatedAuditoryAuditory PerceptionAwardBasic ScienceBiological AssayBiomedical ResearchBiometryCenter for Translational Science ActivitiesCenters of Research ExcellenceChildCitiesClinicalClinical InvestigatorClinical ResearchClinical TrialsComplementDevelopmentDrug Delivery SystemsDrug PrescriptionsDrug ScreeningEconomic BurdenEligibility DeterminationEnsureEnvironmentEtiologyEvaluation ResearchExposure toFetal Alcohol Spectrum DisorderFosteringFoundationsFunctional disorderFundingFunding MechanismsFutureGenetic PolymorphismGenomicsGoalsGrantGreat PlainsHealthHealth systemHearingHearing problemHospitalsHumanImpaired cognitionIncomeIndividualInfantInflammationInfrastructureInstitutionInternationalInterventionInvestigationInvestigational DrugsInvestigational New Drug ApplicationLabyrinthLanguageLeadLifeLongevityMalignant NeoplasmsMedicalMedical centerMental DepressionMentorsMentorshipMilitary PersonnelMitochondriaMulticenter StudiesNebraskaNeonatal Intensive Care UnitsNeural PathwaysNoiseNoise-Induced Hearing LossOccupationalPeripheralPersonsPharmacologic SubstancePhasePilot ProjectsPopulationProductionQuality of lifeRecreationRehabilitation therapyResearchResearch ActivityResearch PersonnelResearch Project GrantsRiskSecureSensoryServicesSocial InteractionStudy SectionSystemTechnologyTherapeuticTherapeutic InterventionTranslatingTranslational ResearchTranslationsUniversitiesWithdrawalaging populationbaseboyscandidate identificationcandidate validationcareercisplatin induced hearing lossclinical centerdrug discoveryefficacy studyefficacy validationfall riskhearing impairmenthearing loss phenotypehearing loss riskhearing preservationhearing restorationhigh risklead candidatemultidisciplinaryneonateototoxicitypatient populationpharmacologicpreclinical studypreservationprogramspsychosocialrecruitsafety studyskillssocialsocioeconomicssuccesstherapeutic candidatetranslational scientistvoucherworking group
项目摘要
PROJECT SUMMARY/ABSTRACT
Overall Plan for the Translational Hearing Center
This Center of Biomedical Research Excellence (COBRE) application is to establish the Translational Hearing
Center, administered by centrally-located Creighton University, with Boys Town National Research Hospital
(BTNRH) and the University of Nebraska Medical Center (UNMC), as institutional partners. Our overall goal is
to build a critical mass of academic translational researchers developing therapeutic interventions to preserve or
restore hearing and vestibular function from a wide range of etiologies that cause hearing loss and vestibular
deficits. Hearing loss in infants and children results in delayed acquisition of listening and spoken language skills
critical for academic achievement and maximal career trajectories of affected individuals. In the aging population,
hearing loss and vestibular deficits without appropriate rehabilitation accelerates aging and cognitive decline.
Aim 1: Develop the infrastructure and expertise base for translational auditory and vestibular research.
COBRE funding will enable an Administrative Core within the Center to provide a unique, transformational
research environment for junior investigators to translate their basic science discoveries into therapeutic
strategies that preserve or restore hearing and vestibular function. This will establish a broader nonclinical
research program. The Administrative Core will coordinate interactions between project leaders with their
Mentors, and an External Advisory Committee. The Administrative Core will develop a Drug Discovery and
Delivery Core that will coordinate necessary drug screen assays and production of derivatives of lead
compounds and their delivery to the inner ear and associated central neural pathways, as well as an Auditory
Vestibular Technology Core to validate the efficacy of lead candidate ototherapeutics hits.
Aim 2: Build a critical mass of funded investigators leading translational auditory and vestibular
research. We will examine both peripheral and central mechanisms of hearing loss and vestibular dysfunction,
and identify pharmacotherapeutic strategies preserve or restore hearing and vestibular function, with multiple
levels of research funding for investigators. We also have an outstanding Mentoring Plan for project leaders,
complementing their expertise with senior investigations as Internal Mentors and biostatistical support, as well
as outside investigators with translational and clinical expertise as External Mentors. Additional mentoring is
provided by Research Core staff, grantsmanship classes and Mock Study Sections of proposals prior to review.
Evaluations of research progress, and all other Center activities, are also key to optimize Center success.
The Center will also benefit from the burgeoning translational research environment in Omaha, Nebraska. Future
plans call for continued expansion of the Center to include submission of Investigational New Drug applications,
safety and efficacy studies and clinical trials in partnership with patient populations served by Creighton
University’s academic medical center, Catholic Health Initiatives (CHI) Health system, BTNRH and UNMC.
项目摘要/摘要
翻译听证中心的总体计划
这个生物医学研究卓越中心(COBRE)的应用是建立转化听证会
中心,由中央位置的克雷顿大学(Creighton University)管理,男孩镇国家研究医院
(BTNRH)和内布拉斯加州大学医学中心(UNMC),作为机构合作伙伴。我们的总体目标是
建立大量的学术翻译研究人员,开发治疗干预措施以保存或
恢复听力和前庭功能,来自多种病因,导致听力损失和前庭
缺陷。婴儿和儿童的听力损失导致听力和口语技能的获取延迟
对学术成就和受影响个人的最大职业轨迹至关重要。在老龄化的人口中,
听力损失和前庭无适当的康复定义会加速衰老和认知能力下降。
目标1:为翻译听觉和前庭研究开发基础设施和专业知识基础。
毛cr融资将使中心内的行政核心能够提供独特的变革性
初级研究人员的研究环境将其基础科学发现转化为治疗
保留或恢复听力和前庭功能的策略。这将建立更广泛的非临床
研究计划。行政核心将协调项目负责人之间的互动
导师和外部咨询委员会。行政核心将开发出药物发现,并
交付核心将协调必要的药物筛选分析和生产铅的衍生物
化合物及其到内耳和相关的中央神经通路以及礼堂
前庭技术核心,以验证铅候选术的效率。
目的2:建立大量资助的研究人员,领先的翻译听觉和前庭
研究。我们将检查听力丧失和前庭功能障碍的外围和中心机制,
并确定药物治疗策略保留或恢复听力和前庭功能,多个
研究人员的研究资金水平。我们还为项目负责人制定了出色的指导计划,
通过作为内部导师和生物统计学支持的高级调查来完成他们的专业知识
作为外部研究人员,具有翻译和临床专业知识为外部导师。其他指导是
由研究核心人员,授予技巧课程和审查前提案的模拟研究部分提供。
研究进度以及所有其他中心活动的评估也是优化中心成功的关键。
该中心还将受益于内布拉斯加州奥马哈市的毛刺翻译研究环境。未来
计划要求继续扩展中心,包括提交调查新药申请,
与Creighton服务的患者人群合作的安全性和有效研究和临床试验
大学的学术医学中心,天主教卫生计划(CHI)卫生系统,BTNRH和UNMC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter Stephen Steyger其他文献
Peter Stephen Steyger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter Stephen Steyger', 18)}}的其他基金
Clinical factors in aminoglycoside-induced ototoxicity
氨基糖苷类引起的耳毒性的临床因素
- 批准号:
10434724 - 财政年份:2019
- 资助金额:
$ 211.6万 - 项目类别:
Clinical factors in aminoglycoside-induced ototoxicity
氨基糖苷类引起的耳毒性的临床因素
- 批准号:
10206090 - 财政年份:2019
- 资助金额:
$ 211.6万 - 项目类别:
相似国自然基金
古代针灸医学学术成就的考证研究
- 批准号:39170907
- 批准年份:1991
- 资助金额:2.5 万元
- 项目类别:面上项目
相似海外基金
Statistical and Machine Learning Methods to Improve Dynamic Treatment Regimens Estimation Using Real World Data
使用真实世界数据改进动态治疗方案估计的统计和机器学习方法
- 批准号:
10654927 - 财政年份:2018
- 资助金额:
$ 211.6万 - 项目类别:
Los Angeles - Southern California (LASC) NIH StrokeNet Regional Coordinating Center
洛杉矶 - 南加州 (LASC) NIH StrokeNet 区域协调中心
- 批准号:
10669559 - 财政年份:2018
- 资助金额:
$ 211.6万 - 项目类别:
Medical University of South Carolina - Cancer Center Support Grant
南卡罗来纳医科大学 - 癌症中心支持补助金
- 批准号:
10589893 - 财政年份:2009
- 资助金额:
$ 211.6万 - 项目类别: